The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Why Integrin as a Primary Target for Imaging and Therapy
Open accessAbstract
Integrin-mediated cell adhesion is involved in many essential normal cellular and pathological functions including cell survival, growth, differentiation, migration, inflammatory responses, platelet aggregation, tissue repair and tumor invasion. 24 different heterodimerized transmembrane integrin receptors are combined from 18 different α and 8 different β subunits. Each integrin subunit contains a large extracellular domain, a single transmembrane domain and a usually short cytoplasmic domain. Integrins bind extracellular matrix (ECM) proteins through their large extracellular domain, and engage the cytoskeleton via their short cytoplasmic tails. These integrin-mediated linkages on either side of the plasma membrane are dynamically linked. Thus, integrins communicate over the plasma membrane in both directions, i.e., outside-in and inside-out signaling. In outside-in signaling through integrins, conformational changes of integrin induced by ligand binding on the extracellular domain altered the cytoplasmic domain structures to elicit various intracellular signaling pathways. Inside-out signaling originates from non-integrin cell surface receptors or cytoplasmic molecules and it activates signaling pathways inside the cells, ultimately resulting in the activation/deactivation of integrins. Integrins are one of key family proteins for cell adhesion regulation through binding to a large number of ECM molecules and cell membrane proteins. Lack of expression of integrins may result in a wide variety of effects ranging from blockage in pre-implantation to embryonic or perinatal lethality and developmental defects. Based on both the key role they played in angiogenesis, leukocytes function and tumor development and easy accessibility as cell surface receptors interacting with extracellular ligands, the integrin superfamily represents the best opportunity of targeting both antibodies and small-molecule antagonists for both therapeutic and diagnostic utility in various key diseases so far.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hynes (2002) · doi:10.1016/s0092-8674(02)00971-6 · Cited by 8,606
Local force and geometry sensing regulate cell functions
Vogel, V., & Sheetz, M. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1890 · Cited by 2,328 · cited 1×
“vary with the cell type, matrix and integrin, and may switch from one adhesion contact to another, contributing to cell advancement, tissue remodeling and repair [7].”
Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels
Brooks, P. C., Montgomery, A. M. P., Rosenfeld, M., Reisfeld, R. A., Hu, T., Klier, G., & Cheresh, D. A. (1994) · Cell · doi:10.1016/0092-8674(94)90007-8 · Cited by 2,262
Immune cell migration in inflammation: present and future therapeutic targets
Luster, A. D., Alon, R., & von Andrian, U. H. (2005) · Nature Immunology · doi:10.1038/ni1275 · Cited by 1,313
Bidirectional Transmembrane Signaling by Cytoplasmic Domain Separation in Integrins
Kim, M., Carman, C. V., & Springer, T. A. (2003) · Science · doi:10.1126/science.1084174 · Cited by 786
Calderwood, D. A., Zent, R., Grant, R., Rees, D. J. G., Hynes, R. O., & Ginsberg, M. H. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.40.28071 · Cited by 720
White, D. E., Kurpios, N. A., Zuo, D., Hassell, J. A., Blaess, S., Mueller, U., & Muller, W. J. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.025 · Cited by 413
Fibronectin matrix deposition and fibronectin receptor expression in healing and normal skin
Clark, R. A. F. (1990) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12876104 · Cited by 312
Growth factor binding to the pericellular matrix and its importance in tissue engineering☆
MACRI, L., SILVERSTEIN, D., & CLARK, R. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.08.015 · Cited by 292
Identification of a novel integrin α6β1 binding site in the angiogenic Inducer CCN1 (CYR61)
Leu, S.-J., Liu, Y., Chen, N., Chen, C.-C., Lam, S. C.-T., & Lau, L. F. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305862200 · Cited by 131
Cited by
Nanomaterials for In Vivo Imaging
Smith, B. R., & Gambhir, S. S. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00073 · Cited by 1,075
Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases
Ha, H., Debnath, B., & Neamati, N. (2017) · Theranostics · doi:10.7150/thno.15625 · Cited by 789
Surface-Engineered Magnetic Nanoparticle Platforms for Cancer Imaging and Therapy
Xie, J., Liu, G., Eden, H. S., Ai, H., & Chen, X. (2011) · Accounts of Chemical Research · doi:10.1021/ar200044b · Cited by 582
Self-citationExploring the Role of RGD-Recognizing Integrins in Cancer
Nieberler, M., Reuning, U., Reichart, F., Notni, J., Wester, H.-J., Schwaiger, M., Weinmüller, M., Räder, A., Steiger, K., & Kessler, H. (2017) · Cancers · doi:10.3390/cancers9090116 · Cited by 429
Clinical Application of Radiolabeled RGD Peptides for PET Imaging of Integrin αvβ3
Chen, H., Niu, G., Wu, H., & Chen, X. (2016) · Theranostics · doi:10.7150/thno.13242 · Cited by 282
Self-citation
Metadata
- Authors
- Niu, G., & Chen, X.
- Venue
- Theranostics
- Publisher
- Ivyspring International Publisher
- Published
- 2011
- Volume
- 1
- Pages
- 30-47
- ISSN
- 1838-7640 (ISSN-L)
- OpenAlex
- W2153771484
- Cited by
- 179
- References
- 10
- FWCI
- 9.59
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Why Integrin as a Primary Target for Imaging and Therapy. https://app.cochat.ai/papers/10.7150/thno/v01p0030
- The paper
- Niu, G., & Chen, X. (2011). Why Integrin as a Primary Target for Imaging and Therapy. Theranostics. https://doi.org/10.7150/thno/v01p0030
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.